Home

Public Policy

Five Strategies for Success: Brave New Biotech World

In the biotech industry’s early days, the benchmark for success for any early-stage company was the nurturing of a biological discovery made in the lab through to market approval.

Regulatory Relief: House Passes SOX Relief Bill

In 2010, a lessening of the regulatory burden on biotech startups looks promising.

It Takes Two: University and Industry Partnerships

When business and academia team up on cutting-edge initiatives, the combination can generate serious revenue and spur the economy.

Biotech Depends on Policies that Promote Innovation

The biotechnology industry’s endeavor to transform science into therapy for a previously untreatable disease is the subject of a new movie, “Extraordinary Measures.”

BioBytes: What are biosimilars?

Biosimilars, also known as follow-on biologics, may eventually expand access and provide patients a more affordable alternative to innovative, lifesaving medicines. 

Get the Scoop on the Presenting Companies for 8th Annual BIO Investor Forum
Indirect Land Use Change, Low Carbon Fuel Standards, & Cap and Trade

Biofuels have the potential to play a critical role in addressing climate change

On GE Animals, Taking Initiative through Guidance on Stewardship

BIO hosted a successful special session on August 20th where the first public presentation was made of the BIO Guidance on Genetically Engineered (GE) Animal Stewardship with 100 international scientists and government officials in the audience of the 7th Transgenic Animal Conference, Tahoe, Calif.

Tools in the 21st Century Tool Box: “Hot Science” on GE Animals

Today’s program at the 7th Transgenic Animal Research Conference in Tahoe, Calif., hit the “hot science”, as one researcher from Germany noted during lunch. The research on genetically engineered (GE) animals will reap huge dividends in societal benefits to solve the world’s most pressing challenges.

The Importance of President Obama's Executive Order on Embryonic Stem Cells

In this interview, BIO President and CEO Jim Greenwood explains the promise of stem cell research and why it is an important first step in bringing new therapies to patients.

U.S. Economic Impact of Advanced Biofuels Production

Total job creation, accounting for economic multiplier effects, could reach 123,000 in 2012, 383,000 in 2016, and 807,000 by 2022.

Guide to Biotechnology 2008

We have used the biological processes of microorganisms for 6,000 years to make useful food products, such as bread and cheese, and to preserve dairy products.

2007-2008 BIO Milestones

Today, the biotechnology industry is enjoying more success and influence than ever before. Our industry’s innovations continue to improve the lives of people worldwide, and the advancement of these innovations is supported by the work of BIO.

Growing The Nation's Biotech Sector

States and regions throughout the United States are investing to create a business climate that supports the specific needs of the biosciences sector.

Milestones in 2006-2007

What happens in Washington influences biotechnology progress every bit as much as what happens on Wall Street or in the lab.

Letters, Testimony & Comments

Transatlantic Trade and Investment Partnership
May 16 2013
Introduction The Biotechnology Industry Organization (BIO) appreciates the opportunity to respond to the Request for Comments issued by...
BIO's letter to FL Governor Scott Regarding Substitution of Biosimilar Medicines
May 8 2013
The Honorable Rick Scott Office of the Governor State of Florida 400 S. Monroe St. Tallahassee, FL 32399-0001 Dear Governor Scott...
PBRER: BIO Comments on Postmarket Periodic Safety Reports in the International Conference on Harmonisation E2C(R2) Format
May 8 2013
  Dear Sir/Madam:   The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for...
Benefit-Risk: BIO Comments on FDA's Prescription Drug User Fee Act V Benefit-Risk Plan
May 7 2013
Dear Sir/Madam: The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to...
Recombinant DNA: BIO Comments on WHO Guidelines on the Quality, Safety, and Efficacy of Biological Medicinal Products Prepared by Recombinant DNA Technology
April 19 2013
  The Biotechnology Industry Organization (BIO) appreciates the opportunity to comment on the “WHO Guidelines on the Quality...
More Letters, Testimony & Comments →

Press Releases

BIO Commends Supreme Court's Support for Continued Biotech Innovation
May 14 2013
Washington, D.C. (May 13, 2013) Jim Greenwood, president and CEO of the Biotechnology Industry Organization (BIO)...
BIO Releases Bioscience Economic Development Report and Guide
April 23 2013
The Biotechnology Industry Organization (BIO) released its “Bioscience Economic Development: Legislative...
BIO Applauds Reps. Hurt and Meeks for Introducing H.R. 1564 to Avoid Burdensome Regulations
April 16 2013
Washington, D.C. (April 16, 2013) Washington, D.C. (April 16, 2013) – The Biotechnology Industry Organization...
Administration’s Budget Proposal Undercuts Development of Cures and Breakthroughs, and Hurts Job Growth
April 11 2013
Washington, D.C. (April 16, 2013) Washington, D.C. (April 16, 2013) – The Biotechnology Industry Organization...
Biosimilars Bill Seeks To Notify Patients & Doctors of Changes to Prescriptions
April 3 2013
Washington, D.C. (April 2, 2013) –  The Biotechnology Industry Organization (BIO) and BioFlorida commend...
More Press Releases →